DrugPatentWatch Database Preview
Sofosbuvir; velpatasvir; voxilaprevir - Generic Drug Details
see a sample report or, see our see our flat-rate plans
What are the generic sources for sofosbuvir; velpatasvir; voxilaprevir and what is the scope of sofosbuvir; velpatasvir; voxilaprevir freedom to operate?
Sofosbuvir; velpatasvir; voxilaprevir
is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sofosbuvir; velpatasvir; voxilaprevir has four hundred and fifteen patent family members in forty-six countries.
There are nine drug master file entries for sofosbuvir; velpatasvir; voxilaprevir. One supplier is listed for this compound.
Summary for sofosbuvir; velpatasvir; voxilaprevir
| International Patents: | 415 |
| US Patents: | 15 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 9 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 7 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for sofosbuvir; velpatasvir; voxilaprevir |
| DailyMed Link: | sofosbuvir; velpatasvir; voxilaprevir at DailyMed |
Pharmacology for sofosbuvir; velpatasvir; voxilaprevir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for sofosbuvir; velpatasvir; voxilaprevir
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,906,880 | Nucleoside phosphoramidate prodrugs | ➤ Sign Up |
| 8,957,046 | Nucleoside phosphoramidate prodrugs | ➤ Sign Up |
| 9,051,340 | Antiviral compounds | ➤ Sign Up |
| 9,156,823 | Antiviral compounds | ➤ Sign Up |
| 9,221,833 | Antiviral compounds | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for sofosbuvir; velpatasvir; voxilaprevir
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Denmark | 2609923 | ➤ Sign Up |
| Chile | 2014003634 | ➤ Sign Up |
| South Korea | 20150034698 | ➤ Sign Up |
| Singapore | 11201408739V | ➤ Sign Up |
| Japan | 2015028060 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for sofosbuvir; velpatasvir; voxilaprevir
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 00704 | Netherlands | ➤ Sign Up | PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117 |
| 0704 | Netherlands | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117 |
| 2014 00061 | Denmark | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894/001-002 20140116 |
| 90066-6 | Sweden | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894 20140117 |
| 14/065 | Ireland | ➤ Sign Up | PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-EU/1/13/894/002 20140116 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Follow DrugPatentWatch: